Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 61 to 75 of 126 results for thyroid* OR hypothyroid* OR Hyperthyroid* OR goiter

  1. Coeliac disease (QS134)

    This quality standard covers recognising, assessing and managing coeliac disease in adults, young people and children. It describes high-quality care in priority areas for improvement.

  2. Irritable bowel syndrome in adults (QS114)

    This quality standard covers diagnosing and managing irritable bowel syndrome in adults. It describes high-quality care in priority areas for improvement.

  3. Bipolar disorder in adults (QS95)

    This quality standard covers recognising, assessing and managing bipolar disorder in adults (aged 18 and over) in primary and secondary care. It describes high-quality care in priority areas for improvement.

  4. Chronic heart failure in adults (QS9)

    This quality standard covers assessing, diagnosing and managing chronic heart failure in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. Statements cover adults with chronic heart failure with reduced ejection fraction and adults with chronic heart failure with preserved ejection fraction, unless otherwise stated.

  5. Dementia: target organ damage (new diagnoses) (IND80)

    This indicator covers the percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded between 6 months before or after entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM09

  6. Learning disabilities: annual TSH test (IND79)

    This indicator covers the percentage of patients on the learning disability register with Down's Syndrome aged 18 and over who have a record of blood TSH in the previous 15 months (excluding those who are on the thyroid disease register). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM04

  7. Diabetes: thyroid disease screening (children) (IND56)

    This indicator covers the proportion of children and young people with type 1 diabetes who have been screened for thyroid disease in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG75

  8. Hypothyroidism: register (IND138)

    This indicator covers the contractor establishing and maintaining a register of patients with hypothyroidism who are currently treated with levothyroxine. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM99.

  9. Promoting health and preventing premature mortality in black, Asian and other minority ethnic groups (QS167)

    This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.

  10. Hypertension in adults (QS28)

    This quality standard covers managing hypertension in adults. It includes diagnosis and investigations, treatment and specialist referral. It describes high-quality care in priority areas for improvement.

  11. Dementia: target organ damage (all patients) (IND118)

    This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72

  12. Are there subgroups of people with Graves' disease who have a particularly good response to antithyroid drugs?

    long-term outcomes than antithyroid drugs in terms of thyroid status, but with a greater risk of thyroid eye disease. There...

  13. Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency (HST7)

    Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency.

  14. Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer who have had surgery and radioactive iodine (RAI), what is the optimal duration of thyroid stimulating hormone suppression?

    NG230/04 Question Duration of thyroid stimulating hormone suppression: For people with differentiated thyroid cancer who...